Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study

This analysis of 5-year Hodgkin lymphoma survivors (n=2,996; range 12-58 years) found the cumulative incidence of severe to fatal chronic conditions by 35 years of age was 31.4% (95% CI, 29.2 to 33.5), with a 20% reduction in risk from the 1970s to the 1990s.

Journal of Clinical Oncology